SELLAS Life Sciences Group (NASDAQ:SLS) Stock Sees Heavy Put Option Buying

SELLAS Life Sciences Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Traders bought 48,643 put options on SELLAS Life Sciences, 19% above its typical daily volume.
  • Shares fell 4.2% to $7.53 on Monday; the stock’s 50-day moving average was $11.03, while its 12-month range was $1.39–$15.88.
  • The company met analysts’ quarterly earnings estimate of a loss of $0.05 per share. Analysts’ consensus rating was Hold, with a $10 price target.
  • MarketBeat previews top five stocks to own in December.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the recipient of some unusual options trading activity on Monday. Stock traders bought 48,643 put options on the stock. This is an increase of 19% compared to the typical daily volume of 40,961 put options.

SELLAS Life Sciences Group Trading Down 4.2%

Shares of SLS traded down $0.33 during trading hours on Monday, reaching $7.53. The stock had a trading volume of 3,178,609 shares, compared to its average volume of 7,843,897. The firm has a 50-day simple moving average of $11.03 and a 200 day simple moving average of $8.77. SELLAS Life Sciences Group has a 12 month low of $1.39 and a 12 month high of $15.88. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -38.10 and a beta of 2.73.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.05).

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Alliance Global Partners reissued a "buy" rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, SELLAS Life Sciences Group has a consensus rating of "Hold" and a consensus price target of $10.00.

Check Out Our Latest Analysis on SLS

Institutional Trading of SELLAS Life Sciences Group

A number of large investors have recently modified their holdings of the business. Nykredit A S bought a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at $27,000. GAMMA Investing LLC lifted its stake in SELLAS Life Sciences Group by 293.2% in the third quarter. GAMMA Investing LLC now owns 2,186 shares of the company's stock worth $27,000 after purchasing an additional 1,630 shares during the last quarter. Sterling Capital Management LLC lifted its stake in SELLAS Life Sciences Group by 900.8% in the third quarter. Sterling Capital Management LLC now owns 6,635 shares of the company's stock worth $82,000 after purchasing an additional 5,972 shares during the last quarter. City State Bank bought a new stake in SELLAS Life Sciences Group in the third quarter worth $100,000. Finally, California State Teachers Retirement System boosted its position in SELLAS Life Sciences Group by 22.4% during the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company's stock valued at $39,000 after buying an additional 1,709 shares during the period. Institutional investors own 17.38% of the company's stock.

About SELLAS Life Sciences Group

(Get Free Report)

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms' tumor 1 (WT1) protein, which is found in several types of cancer.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SELLAS Life Sciences Group Right Now?

Before you consider SELLAS Life Sciences Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.

While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines